首页 > 最新文献

Australian Prescriber最新文献

英文 中文
Therapeutics for rheumatic fever and rheumatic heart disease. 治疗风湿热和风湿性心脏病。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.034
Anna P Ralph, Bart J Currie

The goals of acute rheumatic fever therapy are to relieve symptoms, mitigate cardiac valve damage and eradicate streptococcal infection. Preventing future recurrences requires long-term secondary antibiotic prophylaxis and ongoing prevention of Streptococcus pyogenes (group A streptococcus) infections The recommended regimen for secondary prophylaxis comprises benzathine benzylpenicillin G intramuscular injections every four weeks. For patients with non-severe or immediate penicillin hypersensitivity, use erythromycin orally twice daily The goals of therapy for rheumatic heart disease are to prevent progression and optimise cardiac function. Secondary antibiotic prophylaxis can reduce the long-term severity of rheumatic heart disease Patients with rheumatic heart disease, including those receiving benzathine benzylpenicillin G prophylaxis, should receive amoxicillin prophylaxis before undergoing high-risk dental or surgical procedures. If they have recently been treated with a course of penicillin or amoxicillin, or have immediate penicillin hypersensitivity, clindamycin is recommended.

急性风湿热治疗的目标是缓解症状、减轻心脏瓣膜损伤和根除链球菌感染。预防未来复发需要长期的二级抗生素预防和持续预防化脓性链球菌（A 组链球菌）感染。风湿性心脏病的治疗目标是防止病情恶化和优化心脏功能。二次抗生素预防可减轻风湿性心脏病的长期严重程度 风湿性心脏病患者，包括接受苄星青霉素 G 预防治疗的患者，在进行高风险牙科或外科手术前应接受阿莫西林预防治疗。如果他们最近接受过一个疗程的青霉素或阿莫西林治疗，或对青霉素过敏，建议使用克林霉素。
{"title":"Therapeutics for rheumatic fever and rheumatic heart disease.","authors":"Anna P Ralph, Bart J Currie","doi":"10.18773/austprescr.2022.034","DOIUrl":"10.18773/austprescr.2022.034","url":null,"abstract":"<p><p>The goals of acute rheumatic fever therapy are to relieve symptoms, mitigate cardiac valve damage and eradicate streptococcal infection. Preventing future recurrences requires long-term secondary antibiotic prophylaxis and ongoing prevention of Streptococcus pyogenes (group A streptococcus) infections The recommended regimen for secondary prophylaxis comprises benzathine benzylpenicillin G intramuscular injections every four weeks. For patients with non-severe or immediate penicillin hypersensitivity, use erythromycin orally twice daily The goals of therapy for rheumatic heart disease are to prevent progression and optimise cardiac function. Secondary antibiotic prophylaxis can reduce the long-term severity of rheumatic heart disease Patients with rheumatic heart disease, including those receiving benzathine benzylpenicillin G prophylaxis, should receive amoxicillin prophylaxis before undergoing high-risk dental or surgical procedures. If they have recently been treated with a course of penicillin or amoxicillin, or have immediate penicillin hypersensitivity, clindamycin is recommended.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"104-112"},"PeriodicalIF":3.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/bf/austprescr-45-104.PMC9427630.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab deruxtecan for breast cancer. 曲妥珠单抗德鲁德替康治疗乳腺癌。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 Epub Date: 2022-06-07 DOI: 10.18773/austprescr.2022.043
{"title":"Trastuzumab deruxtecan for breast cancer.","authors":"","doi":"10.18773/austprescr.2022.043","DOIUrl":"https://doi.org/10.18773/austprescr.2022.043","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"146"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/99/austprescr-45-146.PMC9427624.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer. 用于皮肤鳞状细胞癌、基底细胞癌、非小细胞肺癌。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.050
{"title":"Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer.","authors":"","doi":"10.18773/austprescr.2022.050","DOIUrl":"https://doi.org/10.18773/austprescr.2022.050","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"136-137"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/25/austprescr-45-136.PMC9427629.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bimekizumab for plaque psoriasis. 比美珠单抗治疗斑块型银屑病。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 Epub Date: 2022-07-07 DOI: 10.18773/austprescr.2022.038
{"title":"Bimekizumab for plaque psoriasis.","authors":"","doi":"10.18773/austprescr.2022.038","DOIUrl":"https://doi.org/10.18773/austprescr.2022.038","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"132-133"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/49/austprescr-45-132.PMC9427631.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guidelines not for everyone. 指导方针并不适合所有人。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.049
Shyan Goh
{"title":"Guidelines not for everyone.","authors":"Shyan Goh","doi":"10.18773/austprescr.2022.049","DOIUrl":"https://doi.org/10.18773/austprescr.2022.049","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"117"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/4d/austprescr-45-117.PMC9427622.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe adverse drug reaction to allopurinol. 别嘌呤醇严重不良反应。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.032
Grace Lucas, Luke Droney
{"title":"Severe adverse drug reaction to allopurinol.","authors":"Grace Lucas,&nbsp;Luke Droney","doi":"10.18773/austprescr.2022.032","DOIUrl":"https://doi.org/10.18773/austprescr.2022.032","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"130-131"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/2b/austprescr-45-130.PMC9427627.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The anticholinergic burden: from research to practice. 抗胆碱能负荷:从研究到实践。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.031
Sarah N Hilmer, Danijela Gnjidic

Drugs with anticholinergic effects are known to cause adverse effects such as dry mouth, constipation and urinary retention. In older people drugs with anticholinergic effects may contribute to cognitive decline and a loss of functional capacity. Many drugs that are not in the anticholinergic drug class also have anticholinergic effects. They include antidepressants, antipsychotics and antihistamines. Taking multiple drugs with anticholinergic effects creates an anticholinergic burden. It is important that clinicians identify which patients are at risk. There are several tools to assess the anticholinergic burden. Clinicians can use these tools to make a pharmacological risk assessment when reviewing a patient's medicines. This can assist decisions about continuing or stopping drugs with anticholinergic effects. Deprescribing drugs with anticholinergic effects has several potential benefits in older people. In addition to reversing adverse effects, deprescribing may prevent problems such as falls.

已知具有抗胆碱能作用的药物会引起诸如口干、便秘和尿潴留等不良反应。在老年人中，具有抗胆碱能作用的药物可能导致认知能力下降和功能丧失。许多不属于抗胆碱能药物类别的药物也具有抗胆碱能作用。它们包括抗抑郁药、抗精神病药和抗组胺药。服用多种具有抗胆碱能作用的药物会产生抗胆碱能负担。重要的是，临床医生要确定哪些患者处于危险之中。有几种评估抗胆碱能负荷的工具。临床医生可以使用这些工具在审查患者的药物时进行药理学风险评估。这有助于决定是否继续或停止具有抗胆碱能作用的药物。对老年人来说，解除抗胆碱能药物的处方有几个潜在的好处。除了扭转不良反应，开处方还可以预防跌倒等问题。
{"title":"The anticholinergic burden: from research to practice.","authors":"Sarah N Hilmer,&nbsp;Danijela Gnjidic","doi":"10.18773/austprescr.2022.031","DOIUrl":"https://doi.org/10.18773/austprescr.2022.031","url":null,"abstract":"<p><p>Drugs with anticholinergic effects are known to cause adverse effects such as dry mouth, constipation and urinary retention. In older people drugs with anticholinergic effects may contribute to cognitive decline and a loss of functional capacity. Many drugs that are not in the anticholinergic drug class also have anticholinergic effects. They include antidepressants, antipsychotics and antihistamines. Taking multiple drugs with anticholinergic effects creates an anticholinergic burden. It is important that clinicians identify which patients are at risk. There are several tools to assess the anticholinergic burden. Clinicians can use these tools to make a pharmacological risk assessment when reviewing a patient's medicines. This can assist decisions about continuing or stopping drugs with anticholinergic effects. Deprescribing drugs with anticholinergic effects has several potential benefits in older people. In addition to reversing adverse effects, deprescribing may prevent problems such as falls.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"118-120"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/5e/austprescr-45-118.PMC9427617.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Erratum: Hormonal contraception and mood disorders [Correction]. 勘误:激素避孕和情绪障碍[更正]。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 Epub Date: 2022-06-23 DOI: 10.18773/austprescr.2022.037

[This corrects the article on p. 75 in vol. 45, PMID: 35755988.].

[这更正了第45卷第75页的文章，PMID: 35755988]。
{"title":"Erratum: Hormonal contraception and mood disorders [Correction].","authors":"","doi":"10.18773/austprescr.2022.037","DOIUrl":"https://doi.org/10.18773/austprescr.2022.037","url":null,"abstract":"<p><p>[This corrects the article on p. 75 in vol. 45, PMID: 35755988.].</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"147"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/93/austprescr-45-147.PMC9427623.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Elotuzumab for multiple myeloma. Elotuzumab用于多发性骨髓瘤。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 Epub Date: 2022-07-07 DOI: 10.18773/austprescr.2022.040
{"title":"Elotuzumab for multiple myeloma.","authors":"","doi":"10.18773/austprescr.2022.040","DOIUrl":"https://doi.org/10.18773/austprescr.2022.040","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"138-139"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/95/austprescr-45-138.PMC9427619.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Off-label drugs for obesity. 标签外治疗肥胖的药物。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.046
Andy Morgan, Liz Sturgiss
The concluding statement ‘They [weight-loss drugs] are useful during the weight loss phase, but are essential in the maintenance phase’ is contentious but presented as fact. Despite these drugs being used for decades, there are still no trials reporting their benefit on end points, such as cardiovascular events and death. A Cochrane review of their longterm effects in people with hypertension found only one randomised trial reporting cardiovascular outcomes. This showed no differences in all-cause mortality or cardiovascular mortality or morbidity.2
{"title":"Off-label drugs for obesity.","authors":"Andy Morgan,&nbsp;Liz Sturgiss","doi":"10.18773/austprescr.2022.046","DOIUrl":"https://doi.org/10.18773/austprescr.2022.046","url":null,"abstract":"The concluding statement ‘They [weight-loss drugs] are useful during the weight loss phase, but are essential in the maintenance phase’ is contentious but presented as fact. Despite these drugs being used for decades, there are still no trials reporting their benefit on end points, such as cardiovascular events and death. A Cochrane review of their longterm effects in people with hypertension found only one randomised trial reporting cardiovascular outcomes. This showed no differences in all-cause mortality or cardiovascular mortality or morbidity.2","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"114"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/6a/austprescr-45-114.PMC9427632.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40361741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Australian Prescriber
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1